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Abstract
The human APOBEC3G is an innate restriction factor that, in the absence of Vif, restricts HIV-1 replication by inducing
excessive deamination of cytidine residues in nascent reverse transcripts and inhibiting reverse transcription and
integration. To shed light on impact of A3G-Vif interactions on HIV replication, we developed a multi-scale computational
system consisting of intracellular (single-cell), cellular and extracellular (multicellular) events by using ordinary differential
equations. The single-cell model describes molecular-level events within individual cells (such as production and
degradation of host and viral proteins, and assembly and release of new virions), whereas the multicellular model describes
the viral dynamics and multiple cycles of infection within a population of cells. We estimated the model parameters either
directly from previously published experimental data or by running simulations to find the optimum values. We validated
our integrated model by reproducing the results of in vitro T cell culture experiments. Crucially, both downstream effects of
A3G (hypermutation and reduction of viral burst size) were necessary to replicate the experimental results in silico. We also
used the model to study anti-HIV capability of several possible therapeutic strategies including: an antibody to Vif;
upregulation of A3G; and mutated forms of A3G. According to our simulations, A3G with a mutated Vif binding site is
predicted to be significantly more effective than other molecules at the same dose. Ultimately, we performed sensitivity
analysis to identify important model parameters. The results showed that the timing of particle formation and virus release
had the highest impacts on HIV replication. The model also predicted that the degradation of A3G by Vif is not a crucial step
in HIV pathogenesis.
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Introduction
Over the past decade, some human innate restriction factors
have been found to attenuate viral replication. These restriction
factors, including human APOBEC3G (apolipoprotein B mRNA
editing enzyme, catalytic polypeptide-like 3G, or A3G), a potent
inhibitor of human immunodeficiency virus type 1 (HIV-1)
infection, have been extensively reviewed in [1–6] among others.
A3G, a member of the APOBEC family, counteracts retroviral
infection primarily by hypermutating retroviral cDNA and by
inhibition of viral reverse transcription and integration. In a HIV-
infected cell, A3G produced by the cell is encapsulated in progeny
HIV-1 particles by binding to the viral RNA genome. When these
viruses are released and infect another cell, A3G causes excessive
C-to-U deamination of the minus strand DNA during reverse
transcription [7–11]. This results in G-to-A hypermutations in the
plus strand cDNA [7–9,12], with a mutational frequency of over
10% [2,13]. It has also been proposed that uracil-DNA
glycosylases, such as UNG2 or SMUG1 may trigger degradation
of uracilated minus strand DNA [14,15]. But, some reports
showed that uracil DNA glycosylases do not contribute to antiviral
activity of A3G [16–18].
It has been suggested that hypermutation may not be the only
A3G activity that restricts HIV replication [19,20]. Deaminase-
independent activities of A3G include, but are not limited to,
inhibiting synthesis of viral cDNA by blocking translocation of
reverse transcriptase along the template RNA [21–23], reduction
in the ability of tRNA
Lys3 primers to initiate reverse transcription
[24,25], blocking integration of the double-stranded viral DNA by
causing defects in cleavage of tRNA
Lys3 primer [18], or inhibiting
nuclear import of pre-integration complex [26]. Although there is
mounting evidence for deaminase-independent activities of A3G,
several reports have suggested that these activities are the results of
over-expression of A3G in cells [27–29]. As mentioned, A3G
normally mediates antiviral activities in the target cells after being
packaged in the newly budded viruses from the virus-producing
cells. Evidence supporting this observation came from studies
performed almost 10 years before discovery of A3G [30–32].
Recently, Chiu et al. have shown that A3G may also restrict HIV-1
infection in resting CD4+ T cells [33]; however, other groups
could not verify this phenomenon [34,35]. Further investigation is
required to illuminate the new potential mechanisms of A3G
against HIV-1.
HIV-1 is a retrovirus, more specifically a lentivirus. It encodes
nine genes, of which gag, pol and env are common to all
retroviruses. The remaining 6 genes (tat, rev, vif, vpr, vpu and nef)
encode proteins with accessory and/or regulatory roles crucial to
HIV pathogenesis [36,37]. Viral infectivity factor (Vif), a 23-kDa
protein, has an important function in HIV infectivity by inhibiting
A3G. It is thought that Vif’s primary mechanism of action is to
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tion and eventual degradation of A3G through the proteasomal
pathway [11,38–41]. Recently, it has been shown that A3G N
terminal is a target of Vif-induced polyubiquitylation [42].
However, some evidence suggests that Vif more directly impedes
A3G incorporation into HIV-1 virions [12,43]. Sequence analysis
studies have shown that an Asp-Pro-Asp motif at positions 128–
130 in A3G is crucially important for binding of Vif to A3G. The
D128K mutation in A3G protects the protein from Vif-induced
degradation [12,44,45]. Mutations at Tyr-124 or Trp-127 make
the protein unable to bind viral RNA and therefore get packaged
into viruses [46–48]. The 124–127 motif is located beside the 128–
130 Vif-binding region in the 3D model structure of A3G shown
in Fig. 1A [47]. This suggests that Vif binding and RNA binding
may be in competition.
Mathematical models have proven valuable in understanding
the dynamics of HIV-1 infection in vivo [49]. In most existing HIV
infection models, subcellular events such as viral genome
replication and integration, production of viral proteins, and
release of new virions are often not explicitly reflected [50–56].
Instead, these extracellular models consider several cycles of
infection where a population of cells can be infected by viruses and
the effects of drug therapies on the number of viruses are studied.
By contrast, intracellular models assuming only a single cycle of
infection have been limited to the study of the kinetics of virus and
host proteins and their interactions to understand the dynamics of
viral replication inside the cells [57,58]. Both types of modeling
give insights into how HIV disease progresses in the body,
however, combining intracellular and extracellular models would
greatly enhance our understanding in this area [59].
In our previous work [60], we used a model of a single cell that
could undergo multiple re-infection as a surrogate for multicellular
infection, to capture both intracellular and extracellular properties
of HIV infection. In the present study, we have developed a multi-
scale system integrating intracellular, cellular and extracellular
processes. This integrated model explicitly includes concepts such
as burst size (the number of viruses released by a cell), proliferation
rate of cells, cell life cycle, virus clearance, and intracellular delays
in viral formation and release from cells, which were not explicitly
described in the previous model. The integrated model is used to
simulate in vitro T cell HIV infection experiments.
Figure 1. APOBEC3G 3D model structure, HIV virion and its life
cycle. (A) 3D model structure of A3G proposed by Zhang et al. [47]. The
124–127 motif (red) is located beside the 128–130 Vif-binding region
(green). (B) HIV particles are surrounded by fatty materials known as the
viral envelope. The matrix formed from p17 protein is another layer
underneath the viral envelope. The particles also contain two exact
copies of RNA strands as well as three essential enzymes required for
replication: reverse transcriptase, integrase and protease. (C) Mecha-
nism of HIV infection including viral entry, genome integration,
production and release of new viral particles, and encapsulation of
A3G into virions is schematically shown. If the released viruses carry
A3G, they are denoted A3G(+) viruses, otherwise they are denoted
A3G(2). When A3G(+) viruses infect the next cell, the packaged A3G has
several activities such as hypermutating the minus strand of viral DNA,
and inhibiting various steps of reverse transcription and integration.
‘‘Null’’ symbols inside the cell represent degradation of Vif, A3G, and
A3G-Vif complex.
doi:10.1371/journal.pcbi.1002371.g001
Author Summary
According to UNAIDS (The Joint UN Programme on HIV/
AIDS) and WHO, HIV/AIDS has killed more than 25 million
people worldwide since its recognition in 1981. Recently,
APOBEC3G, a member of the APOBEC family, has been
shown to be a potent inhibitor of HIV infection. In contrast,
a viral protein, called Vif, is known to protect the virus by
binding to APOBEC3G and causing the degradation of this
enzyme. We have developed a computational model to
simulate in vitro experiments that include A3G-Vif interac-
tions at the intracellular level and T cell-HIV dynamics at
the multicellular level. Experimental data were used to
establish system parameters and also to validate predic-
tions of our models. We studied various drugs targeting
APOBEC3G and Vif pathways to find the optimum
therapeutic approach against HIV replication. Our model
predicted that a mutated form of APOBEC3G that does not
bind to Vif performs significantly better at suppressing HIV
replication compared to other drugs. We also found that
the drug should be administered shortly after infection
and it must be available to all cells in order to be effective.
Model of Vif and APOBEC3G
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between Vif, virus RNA and human A3G. Experimental data
are used to establish system parameters such as degradation rate
constants of proteins, life-span of infected cells, and viral
generation time. The intracellular model sheds light on how
changes in the intracellular parameters affect the production and
release of new HIV viruses. The single-cell model results are
integrated into a multicellular model to simulate T cell culture
experiments. We estimate certain parameters such as viral burst
size, HIV infectivity rate, and virus clearance rate using
experimental data, and model predictions are verified using
previously published experimental results. Biologically relevant
levels of host and virus proteins in experiments are estimated using
our multi-scale system. We monitor how the population of cells
acts in response to virus infection. Several drugs targeting A3G
and Vif pathways are studied to compare their efficacy at different
doses. We also estimate drug efficacy under non-ideal conditions,
such as when it is available to only a specific fraction of cells in the
whole population, or delivered at later times following infection.
Methods
HIV Biology and System Model
HIV particles are surrounded by a fatty membrane known as
the viral envelope. There is another layer underneath the viral
envelope called matrix which is formed from p17 protein. HIV has
three essential enzymes required for replication: reverse transcrip-
tase, integrase and protease. These enzymes along with two exact
copies of RNA strands are packaged in the viral core or capsid.
This is also where the A3G is encapsulated into the virus. The viral
core is made from the protein p24. A generic structure of HIV
virus is shown in Fig. 1B.
Fig. 1C shows the schematic model of HIV infection that is used
to develop the computational model, capturing both intracellular
and extracellular information. Each cycle of infection begins with
a HIV virus attacking a healthy normal cell. After the virus entry
into cells, the HIV genome is reverse transcribed into cDNA [61].
Some evidence suggests that HIV capsid remains intact during
reverse transcription and that uncoating occurs at the nuclear pore
upon completion of reverse transcription, reviewed in [62]. The
resulting double-stranded DNA enters the nucleus along with the
viral integrase, which splices the HIV DNA into the human
genome. The integrated viral DNA, called provirus, is then
transcribed into messenger RNA used as a blueprint for making
new HIV proteins and enzymes. Some of the viral RNA remains
as full-length RNA copies, to be incorporated as viral genetic
material for new virions. We model the mechanisms from virus
entry to viral protein production using relevant kinetics and
intracellular delay parameters. The focus of this study is the
interaction between Vif and A3G, and their productions are
explicitly included in our model.
HIV enzymes, structural proteins, and full-length RNA
molecules are assembled into virions at the cell membrane.
Human T cells can produce A3G as an intrinsic defense
mechanism. This protein binds the viral RNA and gets
encapsidated into the viral capsids while they are still inside the
cell. Shortly after viral assembly, the viruses get released from the
cells and they are ready to infect new cells. In our model, if the
released viruses carry A3G, they are denoted A3G(+) viruses,
otherwise they are denoted A3G(2). The encapsulated A3G is
assumed to not have effects on viral entry. This is simply because
the entry process involves the binding of CD4 and chemokine
coreceptors on the T cell surface to gp41 and gp120 on the viral
envelope whereas A3G is encapsulated inside the capsid and
doesn’t interact with the proteins on the viral envelope. When
A3G(+) viruses infect the next cell, the packaged A3G can have
various anti-retroviral activities. In this paper, we focus on two
downstream effects of A3G; 1) hypermutation in the minus strand
of viral DNA; and 2) inhibition of viral cDNA production. This
means that even though A3G(+) viruses can infect cells with similar
rate of infectivity to A3G(2) viruses, infected cells produce fewer
virions. HIV has evolved to combat A3G with Vif. The Vif protein
binds A3G and facilitates its polyubiquitylation, and therefore
increases its degradation rate. This Vif-induced degradation, and
basal rates of degradation of both Vif and A3G, are included in the
model. Note that we assume A3G doesn’t affect replication of
viruses in the producer cell. This has been observed in [30–32]
and can be explained assuming that reverse transcription occurs
inside the capsid and A3G doesn’t have access to transcripts. The
single-cell and multicellular models of HIV infection are described
using differential equations.
Mathematical Model Development for Intracellular
Interactions (‘‘Single-Cell Model’’)
Our model includes both proteins and virions in a generic
human T cell. There is a differential equation for each entity,
which describes its production, degradation, and interactions with
other entities.
The A3G protein can be produced, degraded, and incorporated
into progeny viruses. It also binds to and dissociates from Vif.
d½A3G 
dt
~PA3G{kd,A3G½A3G {kon½Vif ½A3G zkoff½A3G:Vif 
{kA3G:HIVsA3GfHIV({)g½A3G ,
ð1Þ
where PA3G is the production rate of A3G, kd,A3G is the degradation
coefficient of A3G, kon and koff are the binding and dissociation
constants of the A3G-Vif complex, and kA3G.HIV is the rate constant
for A3G incorporation into A3G(2) HIV viruses, denoted by
HIV(2). The stoichiometry of A3G proteins incorporated into
virions is sA3G. Similarly, Vif concentration is governed by
d½Vif 
dt
~PVif{kd,Vif½Vif {kon½Vif ½A3G zkoff½A3G:Vif , ð2Þ
where PVif and kd,Vif are the production rate and the degradation
coefficient of Vif, respectively. The A3G-Vif complex can be
formed from Vif binding to A3G or it can degrade.
d½A3G:Vif 
dt
~{kd,A3G:Vif½A3G:Vif z
kon½Vif ½A3G {koff½A3G:Vif ,
ð3Þ
In (3), the degradation coefficient of A3G-Vif complex is shown by
kd,A3G.Vif. The number of HIV virions inside the cell is also
modeled by
dfHIV({)g
dt
~PHIV{kA3G:HIVfHIV({)g½A3G {krelfHIV({)g: ð4Þ
Viruses are produced at a rate of PHIV and budded off from the cell
by a rate of krel. The A3G protein can get encapsulated into
A3G(2) viruses and convert them to A3G(+) viruses. The number
of intracellular A3G(+) viruses is governed by
dfHIV(z)g
dt
~kA3G:HIVfHIV({)g½A3G {krelfHIV(z)g, ð5Þ
Model of Vif and APOBEC3G
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made HIV viruses is described by the following equations.
M({)(t)~
dfHIVrel,({)g
dt
~krelfHIVrel,({)g, ð6aÞ
M(z)(t)~
dfHIVrel,(z)g
dt
~krelfHIVrel,(z)g: ð6bÞ
In equation (6), HIVrel,(2) and HIVrel,(+) represent released A3G(2)
and A3G(+) viruses, respectively. M(2)(t) and M(+)(t), the number of
released A3G(2) and A3G(+) viruses at time t, will be used later in
the extracellular model. In the model, proteins are quantified in
units of molar concentration, whereas viruses are quantified as
discrete numbers of viral particles. Fig. 2 shows the time evolution
of total number of A3G(2) and A3G(+) viruses produced in a
single cell after infection and released from it to the extracellular
environment.
Mathematical Model Development for Extracellular
Events (‘‘Multicellular Model’’)
Our multicellular model describes an extracellular pool of HIV
viruses infecting a population of T cells, specifically, in cell culture.
This model includes cellular and extracellular properties including
the production rate of T cells, rate of infection by HIV viruses,
variations in levels of A3G(2) and A3G(+) viruses, and burst size
(which is defined as the average number of HIV viruses made by
an infected cell). There is a strong link between the intracellular
and multicellular models through the burst size and the release
distribution of A3G(2) and A3G(+) viruses over time. The
multicellular model can be described by a set of equations and
constraints. In our model, we define T0 as the initial number of
‘‘Normal’’ T cells. Each cell lives in the normal state until a HIV
virus infects it. ‘‘Infected(+)’’ and ‘‘Infected(2)’’ states correspond
to cells that have been infected by A3G(+) and A3G(2) viruses,
respectively; however, infected(+) cells produce fewer viruses than
infected(2) cells. It is assumed that there is no hyper-infection, that
is, after a virus attacks and enters a healthy cell, the cell becomes
infected, CD4 is down-regulated [63], and no more viruses attack
it. Cells in infected(+) and infected(2) states become ‘‘Produc-
tive(+)’’ and ‘‘Productive(2)’’ after Dt=tprod post infection,
respectively and begin releasing viruses into the extracellular
environment. The release continues until Dt=t dead after infection,
when the cell dies and it is marked ‘‘Dead’’. A schematic diagram
of cell states is shown in Fig. 3A.
Fig. 3B is a snapshot of the multicellular model at a specific
time, showing cells of different post-infection ages at different
states. In our simulations, we keep time of infection for each cell in
the multicellular model. This is represented by early and late
infected cells in the set of infected cells and by early and late
productive cells in the set of productive cells.
The number of healthy and infected cells in our model is
governed by the following equations.
dT(t)
dt
~kpT(t){kinf(V({)(t)zV(z)(t))T(t), ð7Þ
and
dTinf , { ðÞ t ðÞ
dt
~kinfV { ðÞ t ðÞ Tt ðÞ {
kinfV { ðÞ t{tprod
  
Tt {tprod
  
,
ð8aÞ
dTinf , z ðÞ t ðÞ
dt
~kinfV z ðÞ t ðÞ Tt ðÞ {
kinfV z ðÞ t{tprod
  
Tt {tprod
  
,
ð8bÞ
where T is the number of healthy cells and the rate of infection is
defined by kinf. The proliferation rate of healthy cells is represented
by kp=ln(2)/tT,2 where tT,2 is the cell doubling time. A3G(2) and
A3G(+) viruses are denoted by V(2) and V(+), respectively, and t
represents time post inoculation of the T cell culture. Note that
V(2)(t), V(+)(t), and T(t) are all zero for t,0. In (7), the number of
normal T cells increases by cell proliferation and decreases as cells
get infected.
In (8a) and (8b), Tinf,(2) and Tinf,(+) represent the number of cells
infected by A3G(2) and A3G(+) viruses, respectively. As
mentioned earlier, each infected cell begins releasing new viruses
after a time tprod post infection. At this point, the infected cells
become actively productive, represented by Tprod,(2) and Tprod,(+).
Note that in (8a), there are two mathematical terms determining
the rate of change for Tinf,(2). The first term, KinfV(2)(t)T(t),
represents the number of cells that become infected by A3G(2)
viruses at time t and enter the set of infected cells, whereas the
second term, KinfV(2)(t2tprod)T(t2tprod), represents the number of
cells that were infected at time t2tprod, i.e., they are productive at
time t and leave the set of infected cells to join the set of productive
cells (Fig. 3B). The mathematical terms in (8b) are the same as
those in (8a), except that they deal with infected(+) cells. The
number of productive cells is described by
dTprod,({)(t)
dt
~kinfV({)(t{tprod)T(t{tprod){
kinfV({)(t{tdead)T(t{tdead),
ð9aÞ
Figure 2. Time-dependent profile of virus release from a single
cell. The time evolution of total number of A3G(2) and A3G(+) viruses
produced inside a single cell and released from it is shown. Infection
occurs at t=0. Production of new viruses begins approximately
16 hours after infection. Light and dark green colors represent
A3G(2) and A3G(+) viruses inside the cell. Newly produced viruses
get released to the extracellular environment at 22 hours post infection
and the virus release continues until the cell dies approximately
55 hours after infection. A3G(2) and A3G(+) viruses outside the cell are
represented by light and dark brown colors.
doi:10.1371/journal.pcbi.1002371.g002
Model of Vif and APOBEC3G
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dt
~kinfV(z)(t{tprod)T(t{tprod){
kinfV(z)(t{tdead)T(t{tdead):
ð9bÞ
In (9a), the first term, KinfV(2)(t2tprod)T(t2tprod), represents the
number of cells that become productive at time t and enter the set
of productive cells. Once the cells are infected with HIV, they have
an average life span of tdead. This means that productive cells
release HIV viruses from tprod until their death at tdead. The second
term in (9a), KinfV(2)(t2tdead)T(t2tdead), represents the number of
cells that were infected at time t2tdead, i.e., they are dead at time t
and leave the set of productive cells (Fig. 3B). The mathematical
terms in (9b) are the same as those in (9a), except that they
describe productive(+) cells. The number of dead cells is
represented by Tdead, governed by
dTdead(t)
dt
~
dTdead,({)(t)
dt
z
dTdead,(z)(t)
dt
~kinfV({)(t{tdead)T(t{tdead)
zkinfV(z)(t{tdead)T(t{tdead):
ð10Þ
Along with the equations for different cell states, the model tracks
extracellular viruses.
Figure 3. A schematic diagram of cell states and a snapshot of the multicellular model. (A) each cell lives in the ‘‘Normal’’ state until a HIV
virus infects it. An ‘‘Infected’’ cell doesn’t release new virions until a certain time point post infection, denoted tprod. At this time point, the cell
becomes ‘‘Productive’’ and begins releasing viruses into the extracellular environment until it dies at tdead, when it is marked as ‘‘Dead’’. The
‘‘Infected(+)’’ and ‘‘Infected(2)’’ states correspond to cells that have been infected by A3G(+) and A3G(2) viruses, respectively. The same concept
applies to ‘‘Productive(+)’’ and ‘‘Productive(2)’’ cells. (B) The time of infection is known for each cell in our multicellular model. A snapshot of the
multicellular model shows cells with different post-infection ages in the sets of infected and productive cells. Normal cells become infected and enter
the set of infected cells as early-infected cells. The late-infected cells become productive and leave the set of infected cells to join the set of
productive cells where they are shown as early-productive cells. Finally, late-productive cells die, exit the set of productive cells, and get markeda s
dead.
doi:10.1371/journal.pcbi.1002371.g003
Model of Vif and APOBEC3G
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dt
~pTprod,({)(t)MavgzpcTprod,(z)(t)Mavg{
kinfV({)(t)T(t){kvV({)(t),
ð11aÞ
dV(z)(t)
dt
~(1{p)Tprod,({)(t)Mavgz
(1{p)cTprod,(z)(t)Mavg{kinfV(z)(t)T(t){kvV(z)(t):
ð11bÞ
The average number of viruses released from a productive(2) cell
is Mavg=B/(tdead2tprod) where B is the viral burst size. The
percentage of released viruses that do not contain A3G is denoted
by p. The encapsulated A3G in the HIV virus has anti-viral
activities in the target cell. This results in that a productive(+) cell
produces fewer viruses than a productive(2) cell. The reduction in
burst size of productive(+) cells is denoted by c. Both p and c take
values between 0 and 1. In (11a), the first and second terms refer to
the number of A3G(2) viruses being produced from productive(2)
and productive(+) cells, whereas the third term represents the
number of viruses that are infecting cells. The last term shows the
number of viruses that are being cleared from the culture. The
clearance rate is represented by kv=ln(2)/tv,1/2 where tv,1/2 is HIV
half-life in vitro. Mathematically similar terms describe the number
of A3G(+) viruses in (11b).
Parameters p and c play important roles in our simulation.
Since p has a direct effect on the shape of HIV replication curves
(described later), we call this parameter HIV replicative
potential. The value of p inversely correlate with intracellular
A3G getting encapsulated in newly made viral particles. It is
desirable for both p and c to have values as close as possible to
zero to efficiently stop HIV replication. Nominal values of p and
c are shown in Table 1 for different types of viruses and cells.
Note that p is a property of cells whereas c is a property of
viruses. To compute the number of A3G(2) and A3G(+)v i r u s e s
in (11a) and (11b), we assumed that the release rate of viruses
from a productive cell over period of [tprod, tdead] is constant and
also p, the HIV replicative potential remains constant during this
period.
As we will see in the results section, the release rate of viruses
from a productive cell is not constant at all times. In fact, virus
release begins at tprod post infection, increases for 8 hours and
remains constant until the cell dies. Also the ratio of released
A3G(2) viruses to total released viruses is not constant during the
virus release period and changes over time as it can be seen in
Fig. 2. Therefore we use the following equations instead of (11a)
and (11b) to accurately compute the number of viruses without
having any assumptions on the release of viruses.
dV({)(t)
dt
~
X
Tprod,({)(t)
i~1
M({)(t{ti)z
X
Tprod,(z)(t)
i~1
cM({)(t{ti){kinfV({)(t)T(t){kvV({)(t),
ð12aÞ
dV(z)(t)
dt
~
X
Tprod,({)(t)
i~1
M(z)(t{ti)z
X
Tprod,(z)(t)
i~1
cM(z)(t{ti){kinfV(z)(t)T(t){kvV(z)(t),
ð12bÞ
M(2)(t) and M(+)(t) are the number of released A3G(2) and A3G(+)
viruses from a single cell at time t after infection, defined in (6a)
and (6b). The first term in (12a) is a summation over all the
A3G(2) viruses that are being released at time t from all the cells
in the set of productive(2) cells. The time of infection for the ith
cell in the set is denoted by ti. The second term in (12a) is similar to
the first term, but deals with the A3G(2) viruses released from the
productive(+) cells. Similar mathematical expressions are used for
computing the number of A3G(+) viruses in (12b).
Viruses in cell culture can become non-infectious or dead after
some time. The number of cleared viruses from the culture is given
by
dVdead(t)
dt
~kv(V({)(t)zV(z)(t)): ð13Þ
Integration of Single-Cell Model Results into the
Multicellular Model
As noted above, the single cell and multicellular models are
linked through the burst size and the release distribution of
A3G(2) and A3G(+) viruses over time. In this paper, we use the
following two methods to establish this link.
In the first method, the multicellular model assumes that release
rate of viruses from a productive cell over period of [tprod, tdead]i s
constant and also that the ratio of released A3G(2) viruses to total
released viruses at each time point during virus release is constant
and equal to p. With these assumptions, V(2)(t) and V(+)(t) can be
easily computed using (11a) and (11b). In the second method, the
multicellular model makes no assumption on the rate of virus
release and uses the actual time-dependent profile of virus release
Table 1. Values of p and c for different cases of viruses and cells.
A3G(2) viruses A3G(+) viruses
Target cells express A3G p=Low, c<1 p=Low, c<Low
Output: A3G(2) and A3G(+) viruses Output: A3G(2) and A3G(+) viruses
Target cells do not express A3G p<1, c<1p <1, c<Low
Output: only A3G(2) viruses Output: only A3G(2) viruses
doi:10.1371/journal.pcbi.1002371.t001
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A3G(+) viruses in culture supernatant by using (12a) and (12b).
Although this method provides a comprehensive link between the
two models, it would be difficult to optimize the system
parameters. Therefore, we use the first method for optimizing
the single-cell and multicellular model parameters. Having done
that, we use the second method for our simulations regarding
effects of A3G-based therapeutic strategies, drug penetrance and
administration time on HIV replication.
Results
Single-Cell Model of APOBEC3G-Vif Interactions
For our simulations, we obtained parameters from published
biological experiments. Several groups have measured the
degradation profiles of Vif and of A3G in the presence and
absence of Vif [38,41,64,65]. First-order kinetic decay curves were
used to approximate the degradation rate of Vif, A3G, and A3G-
Vif complex from this experimental data as 0.25 hr
21, 0.1 hr
21,
and 0.3 hr
21, respectively (Figs. 4A–C). The binding affinity of
A3G to Vif has been estimated to be in the low micromolar range
by surface plasmon resonance [66]. We assume a value of 1 mM
for the binding affinity, and calculate kon by assuming
koff=3600 hr
21. The stoichiometry of A3G and HIV, i.e., the
number of A3G proteins incorporated into a virion, sA3G, has been
estimated at seven molecules [67]. In an infected cell, viral protein
production does not start as soon as HIV enters in the cell. Based
on published experimental studies, Vif production begins approx-
imately 12 hours after infection (tprod,Vif=12 hr), increases
through 24 hours (Dtrise,Vif=12 hr) and remains roughly constant
after that. This was experimentally observed by measuring
expression of HIV-1 RNA transcripts during HIV infection in
[68,69] and computationally verified in [57]. HIV particle
formation is assumed to begin 16 hours post infection (tform,-
HIV=16 hr), continue to increase for 8 hours (Dtrise,HIV
form=8 hr) and plateau after that. In addition, a 6-hour delay is
assumed for the budding process, meaning that virus release
begins at 22 (trel,HIV=22 hr) and increases through 30 hours post
infection (Dtrise,HIV rel=8 hr). These assumptions are consistent
with measurements of reverse transcriptase activity in cell culture
supernatants indicating active release of viruses from cells [69] and
with the predictions of theoretical modeling [57].
Using the above parameters as a basis, we estimated the
production rates of A3G and Vif. We have not found experimental
data quantifying these production rates, therefore, we estimate
these parameters using data from [11]. In those experiments, 293T
cells were used as a ‘permissive’ cell line, meaning that they did not
express A3G intrinsically. These cells were co-transfected with two
vectors: one either a wild-type (WT) or a Vif-deficient (DVif) X4
provirus; the other (at varying doses) encoding A3G. After a day,
the levels of supernatant p24 protein in the culture were
monitored. The number of viruses can be calculated from this,
as the 24-kDa p24 protein is estimated to be present at 2000–4000
molecule per virion [70], therefore 1 pg p24<12,500 HIV
particles. The supernatant including viruses from the infected
293T cells was extracted, normalized by p24 content, and used to
challenge indicator cell lines in a single-cycle infection assay in
which expression of chloramphenicol acetyltransferase (CAT)
indicated HIV infection. After 28 hours, the number of infected
cells were measured and normalized [11]. We use the single-cell
model to find the percentage of released A3G(2) viruses in culture
in the transfection part of this experiment and employ the
multicellular model with equations (11a) and (11b) for the
inoculation of CAT-indicator cells. Although the first part of this
algorithm is a transfection of a T cell culture, information on the
number of cells and transfection efficiency was not available.
Moreover, we know that cells begin releasing viruses 22 hours
after infection and in this experiment the culture supernatant was
extracted 24 hours after transfection. This means that viruses in
Figure 4. Degradation profile of protein entities in the model.
Using experimental data and first-order decay curves, degradation
coefficients of (A) Vif, (B) A3G, and (C) A3G-Vif complex were estimated
to be 0.25 hr
21, 0.1 hr
21, and 0.3 hr
21, respectively (re-plotted from
Benedict et al. [60]).
doi:10.1371/journal.pcbi.1002371.g004
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first two hours after transfection. Therefore, asynchronous
infection would not be an issue in this case. This justifies using
the single-cell model for the transfection part of this experiment.
Estimation of Vif and A3G production rates required an
exhaustive search in PVif-PA3G domain. The procedure is as follows.
For a given pair of (PVif, PA3G), the single-cell model computes the
HIV replicative potential, the percentage of released viruses that
are A3G(2). Next, in the multicellular model, CAT-indicator cells
(T0=500,000 cells) are inoculated by viruses corresponding to
5 ng p24 with the ratio of A3G(2) to total viruses equal to p. The
simulations are run for three different doses of A3G as in the
experiment: (PVif, PA3G), (PVif, PA3G/3), and (PVif, PA3G/6), and the
number of infected cells at 28 hours is computed, normalized and
compared to the experimental results to calculate the fitness error
which is defined as the square root of sum of squares of differences
between experimental data and computed results. For the HIV-
DVif case (PVif=0mM/hr), the error for a range of PA3G is
depicted in Fig. 5A and the minimum error is achieved at
PA3G=0.085 mM/hr.
In contrast, Fig. 5B shows the error for the HIV-WT case for a
wide range of values of PVif and PA3G. The fitness increases from
low to high as the color changes from red to dark blue. This figure
gives us possible pairs of (PVif, PA3G) producing best fits to the
experimental data. Based on the value of PA3G obtained from
Fig. 5A, the best fit is achieved at PVif=33mM/hr. The
experimental data from Sheehy et al. [11] used for calculating
PVif and PA3G is re-plotted as blue bars in Figs. 5C and 5D for WT
and DVif viruses, respectively. The red bars show model
predictions of percentage of CAT cells infected by using optimized
PA3G and PVif in our simulations.
The estimates of PA3G and PVif were computed for an assumed
value of kA3G.HIV=50mM
21/hr, because A3G incorporation rate
is not known. We repeated the simulations for a range of kA3G.HIV
values and estimated values of PA3G and PVif with the minimum
error are shown in Fig. 5E and Fig. 5F. We found that PA3G is
inversely proportional with kA3G.HIV, whereas PVif remains
approximately constant. For the rest of this paper, we use the
average value of PVif, which is equal to 35.6 mM/hr. For the
estimation of PVif and PA3G, optimal values for burst size, infectivity
rate and HIV half-life in vitro were used in the multicellular model.
These parameters will be discussed in the next section.
Multicellular Model of HIV Propagation in Culture
For the HIV replication experiments that we are simulating in
this section, unlike the single-round infectivity experiments above,
there is sufficient time for new viruses released by the cells to infect
other cells. In these simulations, we assume that permissive or non-
A3G expressing CEM-SS cells are used, with tT,2=30 hours
(kp=0.5545 day
21) [71,72]. In the multicellular model, we focus
on the release of new HIV. This begins approximately 0.9 days
post infection [53,57,69], so tprod=22 hours. Also, on average a
life-span of 2.3 days was estimated for infected cells [53], therefore
tdead=55 hours. In exploring the multicellular model, we assume
that the release rate of viruses is constant during the productive
phase. Later, when we integrate the single-cell model, the actual
time-varying distribution of virus release is employed. Several
estimates using different techniques are available, ranging from a
hundred to a few thousand viruses per cell [73–79]. HIV clearance
rate in vivo has been estimated in the range of a few hours to a
couple of days [53,80–82], however, measurements of HIV
clearance rate in vitro are not available. Using experimental data
in [11], we estimate kinf, B, and tv,1/2. In [11], CEM-SS cells
(T0=500,000) were stably co-transfected with either an A3G- or
neo-encoding vector. Then, both cell lines were inoculated by
either DVif or WT viruses with an initial dose of 1 or 10 ng p24.
Accumulation of p24 in the culture supernatants was monitored
over time. As expected, efficient replication of both WT and DVif
viruses was observed in the neo-expressing cells. The A3G-
expressing cells also supported WT virus growth, however, very
low replication of DVif viruses was observed.
Since WT HIV replication in both neo- and A3G-expressing
cells were almost the same, we conclude that the amount of A3G
was insufficient to have a large effect on WT HIV replication,
suggesting that Vif had completely inhibited A3G and most of
newly produced viruses did not contain A3G. Therefore, even
though we have A3G-expressing cells, we assume p=1. Hereafter,
we dismiss neo-expressing cells and only focus on A3G-expressing
cells. Data points taken from the published experiments describing
the increase in WT HIV numbers in vitro are shown in Fig. 6A with
red and blue squares representing 1 and 10 ng p24 input HIV,
respectively. As seen in Fig. 6A, data points corresponding to 1 ng
p24 start at 0.1 ng p24/ml on day 3 after inoculation of cell
culture. This means that the volume of cell culture was equal to
10 ml. In our simulations, the blue data points (10 ng p24) are
used as training data for parameter estimation. Then, we change
the initial dose to 1 ng p24 while keeping the estimated parameters
fixed and run the model to examine how well it can reproduce the
red data points.
Given a specific value for viral half-life tv,1/2, we used the default
nonlinear curve-fitting function in Matlab to find the optimum
pair of burst size and infectivity (B, kinf) such that the simulated
HIV growth curve fits the experimental data (WT - 10 ng p24)
with the minimum fitness error. This error is the discrepancy
between experimental and computational results defined by
square root of sum of squares of differences between experimental
data and computed results at each observation time point. We
studied the effects of HIV half-life and cell doubling time on these
estimates of optimal B and kinf in Fig. 7A and Fig. 7B. As tv,1/2
increases, the estimated value of kinf decreases while estimated
burst size stays roughly the same. However, as tT,2 changes from
18 to 48 hours, the estimates of B increase approximately from
400 to 5900 while the values of kinf decrease less than an order of
magnitude. This is reasonable in a sense that in order to get the
same amounts of HIV output as tT,2 increases, viruses must infect
with lower rates (kinf Q), however, they must produce more
progeny in the cells (B q). Since we know tT,2=30 hours, only the
optimum values of B and kinf for each value of tv,1/2 are shown in
Table 2.
For each set of parameters in Table 2, simulated HIV growth
curves are shown in Fig. 6A with dark blue representing tv,1/
2=24 hours and light blue representing other values for tv,1/2 in
the range of 4 hours to infinity. The curves overlap and are a good
fit for the blue squares. HIV growth curves with the same
parameters and 1 ng p24 HIV input are also depicted in Fig. 6A
with dark (tv,1/2=24) and light (tv,1/2=4 … Inf) red colors. Again,
it is observed that all the curves are similar and provide a good fit
for the red data points, with the exception of the last square, which
we will discuss later. Therefore, none of the tested values for viral
half-life, tv,1/2, can be dismissed at this point, since all of them have
generated good fits for the experimental data.
Now, we focus on the experimental data obtained from 10 ng
p24 DVif viruses (blue circles in Fig. 6B). HIV growth curves
corresponding to different values of tv,1/2 increasing from the lowest
curve to the highest one are also shown in Fig. 6B. These curves
were generated as follows. For each triplet of values for (tv,1/2,
B, kinf) from Table 2, the optimal values of p and c between 0 and 1
were chosen using Matlab’s built-in nonlinear curve-fitting function
Model of Vif and APOBEC3G
PLoS Computational Biology | www.ploscompbiol.org 8 February 2012 | Volume 8 | Issue 2 | e1002371Figure 5. Estimation of A3G and Vif production rates. (A) shows the optimum PA3G for the DVif case (PVif=0), whereas (B) shows the fitness
error heat-map for a wide range of values of (PVif, PA3G) for the WT case. The error decreases as color changes from dark red to dark blue. The optimum
PA3G can be read from (A) and projected to the dark blue region of (B) to find the optimum PVif. The experimental data from Sheehy et al. [11] were
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from experimental data). Although all the values of tv,1/2 could
provide a good fit to theexperimentaldata points inFig.6A, they all
failed to produce good fits to the blue circles in Fig. 6B except tv,1/
2=24 which provided a good match with p=0.008 and c=0.008.
Therefore, we conclude that HIV half-life in vitro is approximately
24 hours and we use this number and corresponding numbers from
Table 2 for burst size and infectivity rate in the rest of this study.
Note that these are the optimal values of tv,1/2, B,a n dkinf that were
used in multicellular model in the last section where we estimated
PVif and PA3G.
In Fig. 6C, red circles correspond to 1 ng p24 DVif input and a
simulation curve using the estimated parameters is superimposed.
This curve is a reasonable fit to the data points except for the last
red circle. Compared to the 10 ng p24 data, the experimental data
points for 1 ng p24 DVif input are noisy, possibly because of the
small amounts of p24 in culture supernatant which are initially
close to the detectable level of the p24 ELISA assay.
At this point, we must ask: why do the simulated HIV growth
curves saturate around 9–10 days after infection in the case of WT
viruses? In order to explain this, we study the distribution of cell
states during the period of post infection. As seen in Fig. 8A for the
used for estimating PVif and PA3G is re-plotted as blue bars for (C) WT and (D) DVif viruses. The red bars show our predictions of percentage of CAT
cells infected by using estimated PA3G and PVif in our simulations. All the results in (A) and (B) are obtained for kA3G.HIV=50mM
21/hr. The optimum
values of (E) PVif and (F) PA3G versus kA3G.HIV are also shown.
doi:10.1371/journal.pcbi.1002371.g005
Figure 6. HIV growth curves for WT and DVif viruses. (A) Inoculation of cultures of 500,000 cells with WT HIV. Blue and red squares represent 1
and 10 ng p24 HIV input, respectively. For a given tv,1/2, values of burst size and virus infectivity rate were estimated such that the resulting simulated
HIV growth curve fitted the blue data point with the minimum fitness error (shown as blue lines for tv,1/2=4, 8, 16, 24, 26, Inf hours). Then, the
estimated numbers were used to predict experimental data points corresponding to 1 ng p24 (shown as red lines). (B) Inoculation by 10 ng p24 DVif
HIV. For each triplet of (tv,1/2, B, kinf) from (A), the values of p and c between 0 and 1 were chosen such that the generated curve provided the smallest
error. None of the values of tv,1/2 produced good fits to the blue circles except tv,1/2=24 hours where p and c were estimated to be 0.008 and 0.008,
respectively. (C) The estimated parameters for tv,1/2=24 hours from (A) and (B) were used to examine how well they could generate a curve to fit
experimental data points corresponding to 1 ng p24 DVif input (red circles). The red dashed line provided an acceptable fit to the data points except
for the last circle where the line diverged. (D) All the experimental data points as well as their HIV growth curves are shown in red and blue colors
corresponding to 1 and 10 ng p24 HIV input. Also, we included crowding effects in our simulation by using a logistic function. The two new curves
drawn in light red (1 ng p24 DVif) and light blue (10 ng p24 DVif) show the HIV growth curves for this case. It can be seen that these curves provide a
better fit to the experimental data than the curves in (C).
doi:10.1371/journal.pcbi.1002371.g006
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beginning of infection until the 8th day. But as infection
progresses, infected cells begin to take over. These cells begin
production of new viruses at around 22 hours after infection so the
dominant cells on the 9th day are productive cells. Finally, viruses
kill the productive cells at around 55 hours post infection and thus
after the 11th day, almost all the cells in the culture are dead.
Therefore, no more viruses can be produced and the HIV growth
curve plateaus. The same scenario is observed in Fig. 8B (WT –
1 ng p24), however, infection progresses more slowly due to
presence of fewer viruses initially. As seen in Fig. 8B, the number
of normal cells is much higher than the previous case in the period
of days 1–9. This explains why the total number of viruses will
eventually be higher than the case of 10 ng p24 WT in Fig. 6A.
The reason is that many more normal cells are available for HIV
infection in the case of 1 ng p24 WT, which results in production
of more viruses in the model. This is a testable prediction of the
model, which would require the experiment to be continued after
10 days.
Looking at Fig. 8D for DVif viruses, we see more than 80
percent of the cells are healthy on the 15th day and the percentage
of dead cells is negligible, in clear contrast to what was seen for
WT viruses in Figs. 8A–B. This is because of the less efficient
propagation of infection of DVif viruses allowing normal
proliferation of healthy cells. This in turn provides yet more cells
for HIV to infect compared to the WT case. In fact, it may explain
the rise of the DVif growth curve in Fig. 6C and its divergence
from the experimental data points. In our model, we have assumed
constant cell proliferation rates, however, cells might slow or even
stop proliferation when the suspension becomes crowded. In order
to test whether this was a possible explanation for the observed
data, we included the crowding effects in our model by using the
logistic function. Therefore, (7) is replaced by
dT(t)
dt
~kpT(t)(1{
T(t)
Tmax
){kinf(V({)(t)zV(z)(t))T(t), ð14Þ
where Tmax is the maximum possible number of normal cells in
culture and we set it to 50,000,000 (5,000,000 cells/ml). Modified
DVif growth curves are shown in Fig. 6D with light blue and red
colors for 10 and 1 ng p24 DVif input, respectively. These curves
show better fits to the experimental data, suggesting that crowding
effects and slow proliferation could explain the experimental
results. The distributions of cells states corresponding to these two
cases are shown in Figs. 8E–F.
Effects of A3G-Based Therapeutic Strategies, Drug
Penetrance and Administration Time on HIV Replication
Using the model parameterized as above, we can compare the
predicted efficacy of several therapeutic approaches targeting Vif-
A3G interactions. Here, we add four specific molecules to the
model and simulate the effect of their intracellular expression. All
four are large proteins, as opposed to small molecules, and
expression would in most cases require gene therapy. However,
small molecules that had similar properties or effects on the
functional A3G-Vif network could be delivered orally or
intravenously [83,84]. The molecules are: Ab-Vif, a high-affinity
antibody to Vif [85]; A3G, APOBEC3G itself, which could be
upregulated by cytokines such as IL-2 [86] or NFAT and IRF
proteins [87]; A3G
DUb, a mutated A3G with lower Vif-induced
degradation rate (e.g., C97A-A3G [88]); and A3G
DVif, a mutated
A3G that does not bind Vif (e.g. A3G/F126-129 [89] and D128K-
A3G [90]).
In the single-cell model, Ab-Vif is modeled as a new protein
with an affinity for Vif 100 times that of A3G. The degradation
Figure 7. Effects of HIV half-life and cell doubling time on virus infectivity rate and burst size. (A) kinf decreases as tT,2 changes from 18 to
48 hours. The same trend is also observed as tv,1/2 increases from 4 hours to infinity. (B) Estimated burst size remains almost the same for different
values of tv,1/2, however, it increases as tT,2 goes up.
doi:10.1371/journal.pcbi.1002371.g007
Table 2. Estimations of burst size and virus infectivity rate for
tT,2=30 hours.
tv,1/2 (hr) Bk inf (day
21)
4 1900 34610
210
8 1900 19610
210
16 1900 11610
210
24 1900 9610
210
36 1900 7610
210
Inf 1900 4610
210
doi:10.1371/journal.pcbi.1002371.t002
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be kd,Vif. Upregulation of A3G is modeled by increasing PA3G.
A3G
DUb is a mutated A3G that binds to Vif, but its complex with
Vif is not degraded faster than unbound A3G. Therefore, the
degradation rate of A3G
DUb-Vif complex is assumed to be kd,A3G.
Finally, A3G
DVif has the binding site for Vif mutated, and so does
Figure 8. Distribution of cell states during the period of post infection. We simulated cultures of 500,000 healthy normal cells inoculated by
either (A) 10 ng p24 or (B) 1 ng p24 WT HIV input. The infected cells start producing new virions after 22 hours and eventually die around 55 hours
after infection. For WT HIV input, most of the cells are dead by the 12th day. In contrast, if we inoculate the cultures with either (C) 10 ng p24 or (D)
1 ng p24 DVif viruses, the healthy cells will still be the majority ones and the number of dead cells is negligible on the 15th day. In a different
scenario, we included effects of cell culture crowding in our multicellular model by using a logistic function. Such cultures inoculated with either (E)
10 ng p24 or (F) 1 ng p24 DVif viruses provide better fits to biological experiments.
doi:10.1371/journal.pcbi.1002371.g008
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therapeutic proteins has the same degradation rate as of A3G. In
our simulations, each of the drugs is expressed in addition to the
cellular A3G produced (at a rate of PA3G). The efficacy of each
drug in terms of reduction in HIV replicative potential versus
various production rates is shown in Fig. 9 for kA3G.HIV=5, 50 and
500 mM
21/hr. Among the therapeutic approaches, Ab-Vif shows
a very poor performance even at very high production rates. It
should be noted that Ab-Vif on its own can only block Vif from
binding to A3G; in other words, it can make A3G more available
but cannot add to its function. At least some A3G must be present
in the cells to get incorporated into HIV particles. This explains
the characteristic plateau as Ab-Vif expression increases (Fig. 9);
beyond this point all A3G is available to be encapsulated. A3G
and A3G
DUb have efficacy profiles that are similar to each other,
both better than that of Ab-Vif. That A3G
DUb is predicted to work
only slightly better than A3G suggests that Vif-induced degrada-
tion of A3G through proteasomal pathway is not central to Vif
effectiveness. A3G
DVif is predicted to be the best therapeutic
approach among these drugs, two orders of magnitude better than
A3G and A3G
DUb. This further suggests that the binding of A3G
to Vif is an important interaction that should be inhibited to block
HIV replication.
We next study A3G
DVif in the multicellular model, assuming
1 ng p24 WT input and kA3G.HIV=50mM
21/hr, although
qualitatively similar results will be obtained for other values of
HIV inputs and kA3G.HIV (data not shown). The intracellular and
multicellular models were coupled using (12a) and (12b) to
compute the total number of A3G(2) and A3G(+) viruses in
culture supernatant. Figs. 10A–D show HIV growth curves
corresponding to various production rates of A3G
DVif. The blue
and red lines represent A3G(2) and A3G(+) viruses, respectively,
whereas, the greens lines represent total viruses in culture
supernatant including A3G(2), A3G(+), and dead ones. As seen
in Fig. 10D, for PA3GDVif=10
2, HIV replication slows more than
two orders of magnitude and A3G(2) viruses reach a level of 10
24
by the 10th day. However, A3G(+) viruses start boosting by the
12th day. As mentioned earlier, this is caused due to an
unconstrained proliferation of normal cells that provides a huge
number of susceptible cells for infection. Similar to before, we
constrained proliferation by including crowding effects using a
logistic function (dashed lines in Fig. 10). In this case, A3G(+)
viruses reach a stable level below 10
21 ng p24/ml and decrease
very slowly up to the 15th day. Therefore, A3G
DVif has actually
been able to stop HIV replication. A comparison of model
predictions using equations (11a/b) or (12a/b) as the coupling
method is shown in Supplemental Fig. S1.
At this point, we are interested to study the effects of drug
penetrance on HIV replication when only a specific fraction of cells
have been transfected (PA3GDVif=10
2). Figs. 10E–H show HIV
growth curves with penetrance=10, 90, 95 and 100% of cells. It is
observed that even if the drug is available to 95%of the cells, viruses
can still actively replicate until they kill all the cells in the solution.
This suggests that the drug must be available to almost 100% of the
cells in order to be effective. HIV growth curves with similar
penetrances for the constrained proliferation case are also depicted
in Figs. 10E–H. Even in this case, there is a large gap between
curves corresponding to 95 and 100% drug availability.
In the next set of simulations, we studied the effects of drug
administration time on the virus replication (PA3GDVif=10
2,
penetrance=100%). As seen inFig.10K, if thedrug is administered
on the 9th day, the HIV growth curve is almost similar to the case
that no drug was available to the cells at all as shown in Fig. 10L.
Note that these results were obtained for in vitro cases, where a
constant source of cell production is not available as opposed to in
vivo cases where old cells proliferate and new cells are born. Also, it
should be mentioned that more than 50% of the cells are either
infected or productive on the 9th day (Fig. 8B) and a lot of viruses
are available in culture supernatant. Therefore, administration of
drug to remaining cells cannot help the culture survive. However,
cells in the culture can still survive if we administer the drug before
the 7th day.Thissuggests that the drug mustbe available to the cells
shortly after inoculation in order for the drugs to be effective. In vivo,
the situation would be different; the constant birth of new cells may
give this therapy greater hope of success.
Sensitivity Analysis: Determining Critical Model
Parameters that Influence HIV Replication
In this section, we analyze the effects of parameter variations in
both single-cell and multicellular models. For the intracellular
model, we investigate the deviations of HIV replicative potential
resulted from +5% change in each of the 17 model parameters
(Fig. 11A). As seen, tform,HIV, the particle formation starting time,
Figure 9. Efficacy comparison of several drugs for different production rates. Efficacy of several proposed therapeutic proteins in reducing
the parameter p estimated using the single-cell model for (A) kA3G.HIV=5, (B) 50 and (C) 500 mM
21/hr. For all cases, A3G
DVif shows a better
performance than other drugs.
doi:10.1371/journal.pcbi.1002371.g009
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release starting time, had the highest negative impact. This
suggests that if the assembly and budding process of HIV particles
from the cells could somehow be slowed, it would have a
significant effect on virus replication. On the other hand, some of
the parameters such as sA3G, burst size, and kd,A3G had very
negligible effects on the intracellular model output.
For the extracellular model, two outputs are considered for
sensitivity analysis; 1) number of healthy cells and 2) number of
A3G(2) viruses on the 6th day. In our simulations, 1 ng p24 WT
HIV input was used for infection without administering any drug.
In terms of the 1st output, almost none of the parameters had a
major impact except the proliferation rate, kp, which produced
high variations in the number of normal cells (Fig. 11B). In
contrast, all the multicellular parameters had significant effects on
the levels of A3G(2) viruses (Fig. 11C). Considering the combined
effects on both outputs, kp was detected as the most sensitive
parameter in the multicellular model.
Discussion
We have developed a mathematical model of the HIV lifecycle
inside and outside of cells, using differential equations. Our model
is the first one developed to specifically couple molecular-level
events within individual cells to the viral dynamics and multiple
cycles of infection within a population of cells. In this paper, we
used two different methods to couple the two models. Estimation
of the system parameters was done using the model with equations
(11a) and (11b) in which the release rate of viruses was assumed to
be constant over period of [tprod, tdead] and also p remained
constant during this period. For the rest of our simulations to study
effects of A3G-based therapies, the model with equations (12a) and
(12b) was used in which the time-dependent distribution of virus
release from a single cell was employed to compute the total
number of A3G(2) and A3G(+) viruses. The multi-scale system
allowed us to achieve a quantitative understanding of the Vif-A3G
pathway in HIV pathogenesis. Experimental data were used to
establish system parameters such as stoichiometry of molecules,
degradation rates of proteins, production profiles of viral proteins,
viral burst size, cell proliferation rate, life-span of infected cells,
viral generation time and virus clearance rate. We validated our
system by reproducing the results of in vitro T cell culture
experiments. We found that both downstream effects of A3G
(hypermutation and reduction of viral burst size) were important
to replicate the experimental results in silico. Based on the model
simulations, in vitro virus clearance was estimated to be 24 hours.
Figure 10. Effects of different production rates, penetrances and administration times of A3G
DVif on HIV growth curve. In all the
simulations, 500,000 cells were inoculated by 1 ng 24 WT HIV input. (A–D) A3G
DVif with different production rates were administered right after
inoculation. The red and blue lines represent A3G(2) and A3G(+) viruses in the culture, respectively. The green lines characterize all the viruses
including A3G(2), A3G(+), and dead ones. For PA3GDVif=10
2, the amount of A3G(2) viruses decay to 10
24 ng p24/ml by the 10th day, however, the
number of A3G(+) viruses rises on the 12th day. Dashed lines represent cultures with constrained proliferation (crowding effects modeled by using a
logistic function). In this case, it is seen that A3G(+) viruses reach a stable level below 10
21 ng p24/ml and decrease very slowly up to the 15th day for
PA3GDVif=10
2. This suggests that A3G
DVif has been able to stop HIV replication. (E–H) Effects of drug penetrance on HIV growth curves. We simulated
cases where the drug was only available to a fraction of cells (PA3GDVif=10
2). Comparing cases corresponding to 95% and 100%, we can see that there
is a gap larger than two orders of magnitude between the total levels of p24 on the 15th day. This implies that drugs should be available to all the
cells to get the desired efficacy. The same qualitative effect is observed in the cultures with constrained proliferation for different drug penetrances.
(I–L) Effects of administration time on HIV growth curves (PA3GDVif=10
2 and penetrance=100%). It is seen that administering drug on the 9th day is
not effective and the results are similar to the case of no drug. However, if the drug is administered before the 7th day, cell could still survive. The
same trend in effects of drug administration time is also observed in cultures with constrained proliferation.
doi:10.1371/journal.pcbi.1002371.g010
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produced by an infected cell is 1900. We simulated two types of T
cell cultures with unconstrained or constrained proliferation rate
(including crowding effects by using a logistic function). It was
observed that simulated HIV growth curves provided better fits to
the experimental data in the latter case suggesting that
proliferation may slow down in cell culture after it gets crowded.
Several therapeutic molecules targeting the Vif-A3G pathway
were tested in our system. These included a high-affinity antibody
to Vif [85], APOBEC3G itself, a mutated A3G with lower Vif-
induced degradation rate (A3G
DUb) [88], and a mutated A3G that
does not bind Vif (A3G
DVif) [89,90]. It was found that A3G
DVif
was the most effective drug that could stop HIV replication. This
also implied that inhibition of A3G binding to Vif is a crucial step
in blocking HIV replication. We further studied A3G
DVif with
respect to effects of penetrance and administration time on HIV
replication. The model predicted that the drug must be available
to almost 100% of the cells in order to get the desired efficacy. Also
it must be available to the cells shortly after inoculation in order
for the cells to survive.
Sensitivity analysis of the single-cell and multicellular models
helped us characterize parameters with significant impacts on the
system. We did a local sensitivity analysis by changing each
parameter by 5% and study their effects on the output
parameters. In the single-cell model, we chose HIV replicative
potential, the ratio of released A3G(2) viruses to the total
number of released viruses, as the output parameter. This is a
critical parameter in our system linking the two models together.
We found that trel,HIV and tform,HIV are the most sensitive
parameters. This implies that slowing the assembly and budding
process of HIV particles from the cells reduces the number of
output A3G(2) viruses. In the multicellular model, two outputs
were chosen for sensitivity analysis: 1) number of healthy cells and
2) number of A3G(2) viruses on the 6th day. We found that the
proliferation rate of cells had the highest combined impact on
both output parameters.
Figure 11. Sensitivity analysis in single-cell and multicellular models. (A) The values of all 17 parameters in the intracellular model have
changed by +5% and the percentage change in p for each of them is shown. Two parameters representing the time origins of virus release and
particle formation had the highest impact on p. In contrast, parameters such as burst size, the degradation rate of A3G, and the stoichiometry of A3G
proteins incorporated in HIV particles had zero or negligible effects on p. For the extracellular model, the effects of parameter variations were studied
on two outputs; (B) number of normal cells and (C) number of A3G(2) viruses on the 6th day. In both cases, variations of cells proliferation rate had
the highest impact on the extracellular model outputs.
doi:10.1371/journal.pcbi.1002371.g011
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processes of HIV infection in vitro, however, this provides the
necessary requirements to expand the model and move towards in
vivo computation modeling of HIV. In the extended model, virus
clearance in vivo and the mechanisms of cell birth, proliferation,
and death would be different and new topics such as latency would
come into play. Also, CD4+ T cells in the immune system can
function as memory cells. Therefore, they can latently carry
integrated HIV for the duration of their lifetime. These cells can
survive for years and possibly decades and upon withdrawal of
antiretroviral therapy, they become active and HIV viral loads
rebound quickly. So, this concept of latency stage should also be
accounted for in the model by having a small population of
dormant infected cells that live for a long period of time and
infrequently become activated to produce HIV. In addition, the
immune system is also hugely diverse and has many more cells
than in vitro cell culture experiments. Also, some tissues such as GI
tract are more susceptible to HIV infection than others. Therefore,
compartmentalization is essential and specific models need to be
developed for each tissue and they must be closely linked to
represent the whole body. The in vivo model will be more
complicated but can answer some more fundamental questions
about HIV pathogenesis than we can not cover with in vitro
modeling.
Supporting Information
Figure S1 Comparison of model predictions using the
two coupling methods. In all the simulations, 500,000 cells
were inoculated by 1 ng 24 WT HIV input. A3GDVif with different
production rates were administered right after inoculation. The
red and blue lines represent A3G(2) and A3G(+) viruses in the
culture, respectively. The green lines characterize all the viruses
including A3G(2), A3G(+), and dead ones. Dashed lines represent
cultures with constrained proliferation (crowding effects modeled
by using a logistic function). The intracellular and multicellular
model were coupled using either (A–D) equations (12a/b) or or
(E–H) equations (11a/b). Although the coupling method using
equations (11a/b) assumes that release rate of viruses from a
productive cell (and the ratio of A3G(2) to total viruses) is constant
over the period [tprod, tdead], it provides a very good approxima-
tion of the model predictions obtained by the second coupling
method using equations (12a/b). Note that there is no assumption
on the rate of virus release in the second method and the actual
time-dependent profile of virus release from a single cell is used to
compute the total number of A3G(2) and A3G(+) viruses in
culture supernatant.
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